Parkman Healthcare Partners LLC acquired a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 55,000 shares of the medical research company’s stock, valued at approximately $8,539,000.
A number of other large investors have also recently bought and sold shares of DGX. Rothschild Investment LLC bought a new stake in Quest Diagnostics in the second quarter valued at $26,000. Innealta Capital LLC bought a new position in Quest Diagnostics in the 2nd quarter worth about $31,000. Larson Financial Group LLC increased its stake in shares of Quest Diagnostics by 77.5% in the second quarter. Larson Financial Group LLC now owns 229 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 100 shares during the period. TruNorth Capital Management LLC bought a new stake in shares of Quest Diagnostics during the second quarter valued at approximately $33,000. Finally, EdgeRock Capital LLC acquired a new position in shares of Quest Diagnostics during the second quarter worth approximately $35,000. Institutional investors own 88.06% of the company’s stock.
Quest Diagnostics Trading Up 0.3 %
Shares of DGX stock opened at $161.94 on Wednesday. The business’s 50 day moving average is $155.95 and its two-hundred day moving average is $149.54. The company has a quick ratio of 1.17, a current ratio of 1.25 and a debt-to-equity ratio of 0.83. Quest Diagnostics Incorporated has a 12 month low of $123.04 and a 12 month high of $165.32. The company has a market cap of $18.07 billion, a PE ratio of 21.77, a price-to-earnings-growth ratio of 2.79 and a beta of 0.89.
Quest Diagnostics Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 29th. Shareholders of record on Tuesday, January 14th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date of this dividend is Tuesday, January 14th. Quest Diagnostics’s dividend payout ratio (DPR) is 40.32%.
Wall Street Analysts Forecast Growth
DGX has been the subject of a number of analyst reports. Barclays boosted their price target on Quest Diagnostics from $154.00 to $168.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 23rd. Piper Sandler raised their price objective on Quest Diagnostics from $150.00 to $165.00 and gave the stock a “neutral” rating in a research note on Monday, October 28th. Truist Financial increased their price target on Quest Diagnostics from $158.00 to $165.00 and gave the company a “hold” rating in a research report on Monday, October 7th. UBS Group upped their price objective on shares of Quest Diagnostics from $165.00 to $166.00 and gave the company a “neutral” rating in a research note on Wednesday, October 23rd. Finally, Evercore ISI started coverage on shares of Quest Diagnostics in a research report on Wednesday, August 28th. They issued an “in-line” rating and a $165.00 price target for the company. Nine analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $164.58.
Check Out Our Latest Research Report on Quest Diagnostics
Insider Buying and Selling at Quest Diagnostics
In related news, SVP Karthik Kuppusamy sold 1,775 shares of the company’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $156.92, for a total value of $278,533.00. Following the completion of the transaction, the senior vice president now directly owns 9,734 shares of the company’s stock, valued at approximately $1,527,459.28. This represents a 15.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Michael J. Deppe sold 18,755 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $154.05, for a total transaction of $2,889,207.75. Following the transaction, the chief accounting officer now directly owns 34,941 shares of the company’s stock, valued at $5,382,661.05. This represents a 34.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.79% of the company’s stock.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Further Reading
- Five stocks we like better than Quest Diagnostics
- How to Use Stock Screeners to Find Stocks
- Kohl’s Faces Holiday Hurdles, But Key Factors Offer Hope
- How to Plot Fibonacci Price Inflection Levels
- Dogs of the Dow: 3 Stocks Poised for a 2025 Rebound
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Atlas Energy Solutions: A New Star in the SmallCap 600 Index
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.